MovDisordV3, PascalFrancis, Corpus, bibRecord, 000A93

Parkinsonism in Patients with a History of Amphetamine Exposure

Identifieur interne : 000A93 ( PascalFrancis/Corpus ); précédent : 000A92; suivant : 000A94

Parkinsonism in Patients with a History of Amphetamine Exposure

Auteurs : Chadwick W. Christine ; Elisabeth R. Garwood ; Lauren E. Schrock ; Daniel E. Austin ; Charles E. Mcculloch

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0303293

Descripteurs français

Pascal (Inist)
- Parkinsonisme, Pathologie du système nerveux, Homme, Amfétamine, Neurotoxine, Vulnérabilité.

English descriptors

KwdEn :
- Amfetamine, Human, Nervous system diseases, Neurotoxin, Parkinsonism, Vulnerability.

Abstract

We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of PD patients with prolonged amphetamine exposure with unexposed PD patients methcathinone. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Parkinsonism in Patients with a History of Amphetamine Exposure`
A11	`01`	`1`		`@1 CHRISTINE (Chadwick W.)`
A11	`02`	`1`		`@1 GARWOOD (Elisabeth R.)`
A11	`03`	`1`		`@1 SCHROCK (Lauren E.)`
A11	`04`	`1`		`@1 AUSTIN (Daniel E.)`
A11	`05`	`1`		`@1 MCCULLOCH (Charles E.)`
A14	`01`			`@1 Department of Neurology, University of California @2 San Francisco, California @3 USA @Z 1 aut.`
A14	`02`			`@1 Pennsylvania State University College of Medicine @2 Hershey, Pennsylvania @3 USA @Z 2 aut.`
A14	`03`			`@1 Department of Neurology, University of Utah @2 Salt Lake City, Utah @3 USA @Z 3 aut.`
A14	`04`			`@1 Colby College @2 Waterville, Maine @3 USA @Z 4 aut.`
A14	`05`			`@1 Department of Epidemiology and Biostatistics, University of California @2 San Francisco, California @3 USA @Z 5 aut.`
A20				`@1 228-231`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000170495040130`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 16 ref.`
A47	`01`	`1`		`@0 10-0303293`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of PD patients with prolonged amphetamine exposure with unexposed PD patients methcathinone. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Homme @5 09`
C03	`03`	`X`	`ENG`	`@0 Human @5 09`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 09`
C03	`04`	`X`	`FRE`	`@0 Amfétamine @2 NK @2 FR @5 10`
C03	`04`	`X`	`ENG`	`@0 Amfetamine @2 NK @2 FR @5 10`
C03	`04`	`X`	`SPA`	`@0 Anfetamina @2 NK @2 FR @5 10`
C03	`05`	`X`	`FRE`	`@0 Neurotoxine @5 11`
C03	`05`	`X`	`ENG`	`@0 Neurotoxin @5 11`
C03	`05`	`X`	`SPA`	`@0 Neurotoxina @5 11`
C03	`06`	`X`	`FRE`	`@0 Vulnérabilité @5 12`
C03	`06`	`X`	`ENG`	`@0 Vulnerability @5 12`
C03	`06`	`X`	`SPA`	`@0 Vulnerabilidad @5 12`
C07	`01`	`X`	`FRE`	`@0 Toxine`
C07	`01`	`X`	`ENG`	`@0 Toxin`
C07	`01`	`X`	`SPA`	`@0 Toxina`
N21				`@1 193`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0303293 INIST
ET :	Parkinsonism in Patients with a History of Amphetamine Exposure
AU :	CHRISTINE (Chadwick W.); GARWOOD (Elisabeth R.); SCHROCK (Lauren E.); AUSTIN (Daniel E.); MCCULLOCH (Charles E.)
AF :	Department of Neurology, University of California/San Francisco, California/Etats-Unis (1 aut.); Pennsylvania State University College of Medicine/Hershey, Pennsylvania/Etats-Unis (2 aut.); Department of Neurology, University of Utah/Salt Lake City, Utah/Etats-Unis (3 aut.); Colby College/Waterville, Maine/Etats-Unis (4 aut.); Department of Epidemiology and Biostatistics, University of California/San Francisco, California/Etats-Unis (5 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 2; Pp. 228-231; Bibl. 16 ref.
LA :	Anglais
EA :	We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of PD patients with prolonged amphetamine exposure with unexposed PD patients methcathinone. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.
CC :	002B17; 002B17F
FD :	Parkinsonisme; Pathologie du système nerveux; Homme; Amfétamine; Neurotoxine; Vulnérabilité
FG :	Toxine
ED :	Parkinsonism; Nervous system diseases; Human; Amfetamine; Neurotoxin; Vulnerability
EG :	Toxin
SD :	Parkinson síndrome; Sistema nervioso patología; Hombre; Anfetamina; Neurotoxina; Vulnerabilidad
LO :	INIST-20953.354000170495040130
ID :	10-0303293

Links to Exploration step

Pascal:10-0303293

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Parkinsonism in Patients with a History of Amphetamine Exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation><inist:fA14 i1="02"><s1>Pennsylvania State University College of Medicine</s1>
<s2>Hershey, Pennsylvania</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, University of Utah</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation><inist:fA14 i1="04"><s1>Colby College</s1>
<s2>Waterville, Maine</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Epidemiology and Biostatistics, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0303293</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0303293 INIST</idno>
<idno type="RBID">Pascal:10-0303293</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A93</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Parkinsonism in Patients with a History of Amphetamine Exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation><inist:fA14 i1="02"><s1>Pennsylvania State University College of Medicine</s1>
<s2>Hershey, Pennsylvania</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, University of Utah</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation><inist:fA14 i1="04"><s1>Colby College</s1>
<s2>Waterville, Maine</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Epidemiology and Biostatistics, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amfetamine</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Neurotoxin</term>
<term>Parkinsonism</term>
<term>Vulnerability</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinsonisme</term>
<term>Pathologie du   système nerveux</term>
<term>Homme</term>
<term>Amfétamine</term>
<term>Neurotoxine</term>
<term>Vulnérabilité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of PD patients with prolonged amphetamine exposure with unexposed PD patients methcathinone. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Parkinsonism in Patients with a History of Amphetamine Exposure</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CHRISTINE (Chadwick W.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GARWOOD (Elisabeth R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SCHROCK (Lauren E.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>AUSTIN (Daniel E.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MCCULLOCH (Charles E.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Pennsylvania State University College of Medicine</s1>
<s2>Hershey, Pennsylvania</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, University of Utah</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Colby College</s1>
<s2>Waterville, Maine</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Epidemiology and Biostatistics, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>228-231</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000170495040130</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>16 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0303293</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of PD patients with prolonged amphetamine exposure with unexposed PD patients methcathinone. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Amfétamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Amfetamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Anfetamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Neurotoxine</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Neurotoxin</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Neurotoxina</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Vulnérabilité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Vulnerability</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Vulnerabilidad</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Toxine</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Toxin</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Toxina</s0>
</fC07>
<fN21><s1>193</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0303293 INIST</NO>
<ET>Parkinsonism in Patients with a History of Amphetamine Exposure</ET>
<AU>CHRISTINE (Chadwick W.); GARWOOD (Elisabeth R.); SCHROCK (Lauren E.); AUSTIN (Daniel E.); MCCULLOCH (Charles E.)</AU>
<AF>Department of Neurology, University of California/San Francisco, California/Etats-Unis (1 aut.); Pennsylvania State University College of Medicine/Hershey, Pennsylvania/Etats-Unis (2 aut.); Department of Neurology, University of Utah/Salt Lake City, Utah/Etats-Unis (3 aut.); Colby College/Waterville, Maine/Etats-Unis (4 aut.); Department of Epidemiology and Biostatistics, University of California/San Francisco, California/Etats-Unis (5 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 2; Pp. 228-231; Bibl. 16 ref.</SO>
<LA>Anglais</LA>
<EA>We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of PD patients with prolonged amphetamine exposure with unexposed PD patients methcathinone. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.</EA>
<CC>002B17; 002B17F</CC>
<FD>Parkinsonisme; Pathologie du   système nerveux; Homme; Amfétamine; Neurotoxine; Vulnérabilité</FD>
<FG>Toxine</FG>
<ED>Parkinsonism; Nervous system diseases; Human; Amfetamine; Neurotoxin; Vulnerability</ED>
<EG>Toxin</EG>
<SD>Parkinson síndrome; Sistema nervioso patología; Hombre; Anfetamina; Neurotoxina; Vulnerabilidad</SD>
<LO>INIST-20953.354000170495040130</LO>
<ID>10-0303293</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A93 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000A93 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0303293
   |texte=   Parkinsonism in Patients with a History of Amphetamine Exposure
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Parkinsonism in Patients with a History of Amphetamine Exposure

Parkinsonism in Patients with a History of Amphetamine Exposure

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri